Centrinone 是 polo 样激酶 4 的可逆抑制剂，对PLK4的Ki值为0.16 nM。

Centrinone (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM).

Centrinone (LCR-263) treatment causes centrosome depletion in human and other vertebrate cells and it treatment reduces centriole number in multiciliated Xenopus epithelial cells, which indicates that Plk4 also controls centriole amplification in differentiated cells. Centrinone (LCR-263) treatment of HeLa human cervical carcinoma cells leads to a progressive reduction in foci containing centriolar and pericentriolar material markers at each round of cell division, until most cells lack centrioles and centrosomes. Centrosome loss irreversibly arrests normal cells in a senescence-like G1 state by a p53-dependent mechanism that is independent of DNA damage, stress, Hippo signaling, extends mitotic duration, or segregation errors[1].

1798871-30-3

C26H25F2N7O6S2

633.65

LCR-263

DMSO:31 mg/mL (48.92 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years